Sunshine Biopharma files to sell up to $4M of common stock in at-the-market offering

Filed July 20, 2026 · ~1 min read

Key Changes

• high

  The company may sell up to $4.0 million of common stock through an at-the-market offering with Aegis Capital as sales agent.

  The Offering verify on EDGAR →
• high

  Net proceeds are intended for general corporate purposes, including working capital, with no minimum offering amount required.

  Use of Proceeds verify on EDGAR →
• high

  The company faces Nasdaq delisting risk after a 10-for-1 reverse split, with an immediate delisting notice possible until June 2027 if the stock trades below $1.00 for 30 consecutive business days.

  Risk Factors verify on EDGAR →